Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Bausch Health Companies Q3 2026 Results: Net Income $436M, Up 143.6% YoY

Bausch Health Companies Inc. reported a total asset decrease to $25.48 billion as of September 30, 2026, compared to $26.37 billion at year-end 2025, primarily driven by a reduction in goodwill and intangible assets. The company's total shareholders' deficit widened to $1.33 billion, while cash and cash equivalents significantly increased to $2.49 billion.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2,941.02,681.0
Profit before tax597.0218.0
Net income436.0179.0
EPS (diluted, $ a share)$1.15$0.48

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+143.6%
Revenue, year on year+9.7%
Operating margin33.4%
Source

10-Q filed with the SEC, NYSE: BHC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Bausch Health Companies Inc.: key numbers

Share price
$8.47Close, Nov 17
Market cap
$3.17B
Shares outstanding
374.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bausch Health Companies Inc.

All →
4:08 PM ET 8-K
Financial Results

Bausch Health Companies Financial Results

Bausch Health reported third quarter 2026 consolidated revenues of $2.94 billion, a 10% increase over the prior year, and GAAP net income of $446 million. The company achieved a milestone with quarterly Adjusted EBITDA (excluding Bausch + Lomb) exceeding $1 billion for the first time and raised its full-year 2026 guidance across revenue and EBITDA metrics.

Term
Q3 2026

“Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth. We also achieved an important milestone, with quarterly Adjusted EBITDA, excluding Bausch + Lomb, exceeding $1 billion for the first time. Our performance reflects disciplined execution across the portfolio, with healthy cash generation supporting more than $500 million of net debt reduction during the quarter. These results give us confidence to again raise our full year 2026 guidance. We remain focused on operational excellence, sustainable growth, and long-term value creation.”

Thomas J. Appio, Chief Executive Officer, Bausch Health

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.